Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.76 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.76 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.68 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MDH1 | P40925 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70173 | 0.91 | CYP4F2 (0.83) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL13554034 | 0.91 | CYP4F2 (0.63) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL1792728 | 0.90 | CYP4A11 (0.75) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL28398121 | 0.88 | CYP4F2 (0.58) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL126284 | 0.87 | LOXL2 (0.74) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL15174508 | 0.87 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5MDH1 | |
| SCHEMBL26239703 | 0.87 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5MDH1 | |
| SCHEMBL15174613 | 0.87 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5MDH1 | |
| SCHEMBL46931 | 0.86 | CYP4A11 (1.00) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL10609527 | 0.86 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102834420-B | Internal and external donor compounds for olefin polymerization catalysts ii | BASF CORP. (US) | 2014-10-22 | — | — | CN | claimed |
| CN-104080824-A | Internal electron donors for olefin polymerization catalysts, methods of making and using the same | BASF CORP | 2014-10-01 | — | — | CN | claimed |
| US-8569195-B2 | Internal and external donor compounds for olefin polymerization catalysts II | BASF CORPORATION (US) | 2013-10-29 | — | — | US | claimed |
| EP-2539375-A2 | INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS II | BASF Corporation (US) | 2013-01-02 | — | — | EP | claimed |
| CN-102834420-A | Internal and external donor compounds for olefin polymerization catalysts ii | BASF CORP | 2012-12-19 | — | — | CN | claimed |
| WO-2011106480-A2 | INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS II | BASF CORPORATION (US) | 2011-09-01 | — | — | WO | claimed |
| US-20110207901-A1 | INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS II | BASF CATALYSTS LLC (US) | 2011-08-25 | — | — | US | claimed |
| US-11241436-B2 | Autophagy inducers for treatment of CNS conditions | NORTHWESTERN UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-10301314-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180162854-A1 | Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| EP-3118226-A1 | HIGH ACTIVITY CATALYST FOR OLEFIN POLYMERIZATION | BASF Corporation (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2782938-B1 | HIGH ACTIVITY CATALYST FOR OLEFIN POLYMERIZATION | BASF CORP (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | JANSSEN SCIENCES IRELAND UC (IE) | 2008-06-19 | — | — | US | disclosed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, RTF2 | CYP4F2 3745/4885CYP4A11 3902/4885LOXL2 1928/4885 |
| US-10301314-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | PGF, BRCA1, RB1 | CYP4F2 1035/4885CYP4A11 510/4885LOXL2 3042/4885 |
| US-20180162854-A1 | Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTC4S, LTB4R | CYP4F2 404/4885CYP4A11 164/4885LOXL2 95/4885 |
| US-11241436-B2 | Autophagy inducers for treatment of CNS conditions | SQSTM1, ATG7, BECN1 | CYP4F2 1083/4885CYP4A11 1410/4885LOXL2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.